Literature DB >> 9603413

Acquired autoimmune thrombocytopenia post-bone marrow transplantation for severe combined immunodeficiency.

S S Ting1, J B Ziegler, M R Vowels.   

Abstract

Children with severe combined immunodeficiency (SCID) have profoundly diminished humoral and cellular immunity resulting in death during infancy unless immune reconstitution occurs by bone marrow transplantation (BMT). Thrombocytopenia post-bone marrow transplantation can be seen in relation to infection, graft-versus-host disease (GVHD) and rarely, as an autoimmune phenomenon due to immune dysregulation. We report two cases of severe AITP following BMT for SCID. Both cases developed large intracerebral hemorrhages from which one died. Autoimmune thrombocytopenia in this setting can be life-threatening and we recommend early and active intervention.

Entities:  

Mesh:

Year:  1998        PMID: 9603413     DOI: 10.1038/sj.bmt.1701168

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  4 in total

1.  Severe autoimmune thrombocytopenia after allogeneic bone marrow transplantation for aplastic anemia.

Authors:  A Tomonari; A Tojo; T Lseki; J Ooi; H Nagayama; K Ogami; T Maekawa; N Shirafuji; K Tani; S Asano
Journal:  Int J Hematol       Date:  2001-08       Impact factor: 2.490

2.  Splenectomy for severe autoimmune cytopenias after allogenic stem cell transplantation: case report.

Authors:  Irena Proleznik; Hugh Grant Prentice; Joze Pretnar; Samo Zver; Peter Cernelc
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

3.  IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).

Authors:  Joanne L Jones; Chia-Ling Phuah; Amanda L Cox; Sara A Thompson; Maria Ban; Jacqueline Shawcross; Amie Walton; Stephen J Sawcer; Alastair Compston; Alasdair J Coles
Journal:  J Clin Invest       Date:  2009-06-22       Impact factor: 14.808

Review 4.  Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program.

Authors:  Eva Havrdova; Jeffrey A Cohen; Dana Horakova; Ivana Kovarova; Eva Meluzinova
Journal:  Ther Clin Risk Manag       Date:  2017-10-16       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.